Robert J. Fox
Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio · Mellen Center for MS / Cleveland Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert J. Fox as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:53 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06190912 · Safety of Bryostatin in Patients With MSRobert Fox · terminated · Multiple Sclerosis
- Ph3NCT05201638 · Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisImmunic AG · active not recruiting · Multiple Sclerosis, Relapsing-Remitting · principal investigator
- Ph3NCT05134441 · Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisImmunic AG · active not recruiting · Multiple Sclerosis · principal investigator
- Ph2NCT05054140 · Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisImmunic AG · unknown · Multiple Sclerosis · principal investigator
- Ph2NCT01982942 · Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisMediciNova · completed · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- N/ANCT01018537 · NARCOMS Registry: A Multiple Sclerosis RegistryUniversity of Texas Southwestern Medical Center · recruiting · Multiple Sclerosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · fiscal years 2025 to 2026 · $1,001,987 awarded in 2026Same name and institution; not confirmed by an ID
- A Cognitive Risk Calculator and Screening tool for Primary Care SettingsR33AG069729 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2022 to 2024 · $1,047,904 awarded in 2024Same name and institution; not confirmed by an ID
- Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)P20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · fiscal years 2022 · $1,100,590 awarded in 2022Same name and institution; not confirmed by an ID
- A Cognitive Risk Calculator and Screening tool for Primary Care SettingsR61AG069729 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2020 to 2021 · $615,414 awarded in 2021Same name and institution; not confirmed by an ID
- Ibudilast Phase II trial in progressive MSU01NS082329 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2013 to 2017 · $284,857 awarded in 2017Grant number is on one of their registry trials
- Brain Atrophy/Diffusion Tensor Study/Multiple SclerosisK23NS047211 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2004 to 2008 · $169,503 awarded in 2008Same name and institution; not confirmed by an ID
- SIGNALING IN CELLS CHRONICALLY EXPOSED TO INTERFERON BETA (NMSS)M01RR018390 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2007 · $200 awarded in 2007Same name and institution; not confirmed by an ID
- MULTIDISCIPLINARY PROGRAM IN SPEECH AND HEARING SCIENCET32DC000051 · NIDCD · OHIO STATE UNIVERSITY · fiscal years 1996 to 2000 · $93,939 awarded in 2000Same name and institution; not confirmed by an ID
- AGE RELATED CHANGES IN THE PERCEPTION OF SPEECHR01AG008353 · NIA · OHIO STATE UNIVERSITY · fiscal years 1989 to 1993 · $143,769 awarded in 1993Same name and institution; not confirmed by an ID
- A STUDY OF THE RHYTHM OF SPOKEN LANGUAGER01NS021121 · NINDS · OHIO STATE UNIVERSITY · fiscal years 1985 · $49,072 awarded in 1985Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:53 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.N Engl J Med · 20081,949 citationsRCR 45.2
- Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med · 20121,092 citationsRCR 34.1
- 730 citationsRCR 31.8
- Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.Ann Neurol · 2008442 citationsRCR 10.2
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.N Engl J Med · 2018230 citationsRCR 9.7
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Neurology · 2009217 citationsRCR 6.4
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.JAMA Neurol · 2021188 citationsRCR 13.4
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.Lancet Neurol · 2021167 citationsRCR 10.2
- MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.Neurology · 2014154 citationsRCR 5.7
- 124 citationsRCR 15.9